Previous studies showed that BRAFi and MEKi treatment could enhance the antigen presentation of melanoma, promote the infiltration of T cells, and induce the expression of PD-L1, thereby modulating the antitumor immune response (Koya et al., 2012; Wilmott et al., 2012; Frederick et al., 2013; Jiang et al., 2013; Knight et al., 2013; Reddy et al., 2016). Here, CD274 is linked to melanoma.